Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demannose SCHEMBL9576995 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Demannose SCHEMBL1277 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Demannose SCHEMBL284703 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Demannose SCHEMBL20956808 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Demannose SCHEMBL20500378 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Demannose SCHEMBL12474438 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Demannose SCHEMBL5070598 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Demannose SCHEMBL17144009 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Galactose SCHEMBL20818999 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Galactose SCHEMBL8371122 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875037-A1 | MEANS FOR COLLECTING A SAMPLE FROM THE RESPIRATORY TRACT | Solvamed GmbH (DE) | 2021-09-08 | — | — | EP | claimed |
| US-10407705-B2 | Fungal cells and fermentation processes | IOGEN ENERGY CORPORATION (CA) | 2019-09-10 | — | — | US | claimed |
| US-20180030492-A1 | FUNGAL CELLS AND FERMENTATION PROCESSES | IOGEN ENERGY CORP (CA) | 2018-02-01 | — | — | US | claimed |
| EP-2791315-A1 | FUNGAL CELLS AND FERMENTATION PROCESSES | Iogen Energy Corporation (CA) | 2014-10-22 | — | — | EP | claimed |
| US-20140295504-A1 | FUNGAL CELLS AND FERMENTATION PROCESSES | IOGEN ENERGY CORPORATION (CA) | 2014-10-02 | — | — | US | claimed |
| WO-2013086633-A1 | FUNGAL CELLS AND FERMENTATION PROCESSES | IOGEN ENERGY CORPORATION (CA) | 2013-06-20 | — | — | WO | claimed |
| CN-102523905-A | Paste root-adhering inoculation method for seeds of cistanche tubulosa | AFFORESTATION AND DESERTIFICATION CONTROL INST XINJIANG ACADEMY OF FORESTRY | 2012-07-04 | — | — | CN | claimed |
| US-20100093660-A1 | ANTI-TUMOR COMPOSITION COMPRISING TISSUE-ACCUMULATING CHITOSAN GEL | ISHIHARA MASAYUKI | 2010-04-15 | — | — | US | claimed |
| EP-2110131-A1 | ANTI-TUMOR COMPOSITION COMPRISING TISSUE-ACCUMULATING CHITOSAN GEL | Yaizu Suisankagaku Industry Co., Ltd. (JP) | 2009-10-21 | — | — | EP | claimed |
| US-6953781-B2 | Compounds and their uses | RODARIS PHARMACEUTICALS LIMITED (GB) | 2005-10-11 | — | — | US | claimed |
| EP-0823903-B1 | HETEROCYCLIC DIARYL COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME, AND USES THEREOF | CT INTERNAT DE RECH S (FR) | 2001-07-18 | — | — | EP | claimed |
| US-6126924-A | Light responsive self-tanning products and methods for use | SCALES-MEDEIROS VIRGINIA A (US) | 2000-10-03 | — | — | US | claimed |
| US-5626839-A | Light responsive self-tanning products and methods for use | SCALES-MEDEIROS VIRGINIA (US) | 1997-05-06 | — | — | US | claimed |
| US-5290764-A | Aqueous buffer and monosaccharide or disaccharide, treatment of fibrinolysis | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-03-01 | — | — | US | claimed |
| US-5272146-A | 1,2-dihydroellipticines with activity against CNS specific cancer cell lines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-12-21 | — | — | US | claimed |
| EP-0332651-B1 | METHOD OF ISOLATING CA 125 ANTIGEN | CENTOCOR INC (US) | 1993-11-18 | — | — | EP | claimed |
| EP-0276551-B1 | COLONY-STIMULATING FACTOR AND METHOD FOR PREPARATION THEREOF | MORINAGA MILK INDUSTRY CO., LTD. (JP) | 1992-03-18 | — | — | EP | claimed |
| EP-0332651-A1 | METHOD OF ISOLATING CA 125 ANTIGEN. | CENTOCOR INC (US) | 1989-09-20 | — | — | EP | claimed |
| EP-0276551-A1 | Colony-stimulating factor and method for preparation thereof | MORINAGA MILK INDUSTRY CO., LTD. (JP) | 1988-08-03 | — | — | EP | claimed |
| WO-1988003954-A1 | METHOD OF ISOLATING CA 125 ANTIGEN | CENTOCOR, INC. (US) | 1988-06-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093660-A1 | ANTI-TUMOR COMPOSITION COMPRISING TISSUE-ACCUMULATING CHITOSAN GEL | CHIA, CROCC, CA14 | LMNA 4446/4885L3MBTL1 4453/4885TDP1 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.